Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of repeated exposure to adjuvanted quadrivalent influenza vaccine in previously vaccinated subjects
2014-002599-95Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in influenza comparing Adjuvanted Quadrivalent Influenza Vaccine with Fluzone Quadrivalent (2 arms). Primary endpoints: Primary immunogenicity objective and Primary safety endpoint. Started Jul 2014; status: terminated.
02
Drugs
MF59-adjuvanted quadrivalent influenza vaccineInfluenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2014-002599-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002599-95.